Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Langsenlehner, T; Langsenlehner, U; Renner, W; Kapp, KS; Krippl, P; Hofmann, G; Clar, H; Pummer, K; Mayer, R.
The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases.
Prostate. 2008; 68(3):264-268
Doi: 10.1002/pros.20682
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Führende Autor*innen der Med Uni Graz
- Langsenlehner Tanja
- Co-Autor*innen der Med Uni Graz
- Clar Heimo
- Hofmann Guenter
- Kapp Karin S.
- Langsenlehner Uwe
- Mayer Ramona
- Pummer Karl
- Renner Wilfried
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Death receptor 4, encoded by the TNFRSF10A gene, is an important mediator of apoptosis and its dysfunction may be related to cancer development and distant tumor spread. A single nucleotide polymorphism in TNFRSF10A (Glu228Ala, rs20576) within a conserved region of the extracellular cysteine-rich domain of death receptor 4 has been associated with an increased risk for a variety of tumor entities. Aim of the present study was to evaluate the role of the TNFRSF10A polymorphism in metastatic progression of prostate cancer after radiation therapy. We carried out a prospective study including 702 prostate cancer patients from the Austrian PROCAGENE (Prostate Cancer Genetics) study. Development of metastases was examined in regular follow-up investigations. TNFRSF10A genotypes were determined by a 5'-nuclease assay (TaqMan). Within a median follow-up time of 10 months (range 0-60 months), 24 (3.4%) patients developed metastases. In a Cox regression model including age at diagnosis and risk group as potential confounders, carriage of an 228Ala allele was associated with a relative risk of 2.47 (95% CI 1.10-5.54; P=0.028) for metastases. TNFRSF10A genotypes were not associated with tumor stage, grade, risk group or age at diagnosis. We conclude that the TNFRSF10A Glu228Ala polymorphism may be a novel independent risk factor for prostate cancer metastases after radiation therapy.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Aged -
- Cohort Studies -
- Cross-Sectional Studies -
- DNA, Neoplasm - chemistry
- DNA, Neoplasm - genetics
- Genotype -
- Humans -
- Kaplan-Meier Estimate -
- Ligands -
- Male -
- Neoplasm Metastasis -
- Polymerase Chain Reaction -
- Polymorphism, Single Nucleotide -
- Proportional Hazards Models -
- Prospective Studies -
- Prostatic Neoplasms - genetics
- Prostatic Neoplasms - pathology
- Protein Structure, Tertiary -
- Receptors, TNF-Related Apoptosis-Inducing Ligand -
- Receptors, Tumor Necrosis Factor - genetics
- Find related publications in this database (Keywords)
- prostate cancer metastases
- prognostic factors
- apoptosis
- death receptor 4
- single nucleotide polymorphisms